Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 7/20 | 0.32 |
| ▸ | GSK3B | P49841 | 7/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523002 | 0.87 | HCAR2 (0.34) | GSK3AGSK3B | |
| SCHEMBL5543611 | 0.78 | KDM5B (0.41) | SYKALDH1A1HSD17B10SMN1; SMN2PARP1 | |
| SCHEMBL3523063 | 0.78 | PDE5A (0.47) | GSK3AGSK3B | |
| SCHEMBL3524484 | 0.78 | PDE5A (0.33) | GSK3AGSK3B | |
| SCHEMBL5548540 | 0.75 | PDE5A (0.32) | GSK3AGSK3B | |
| SCHEMBL3527144 | 0.75 | RAB9A (0.44) | MAPK1KMT2ALMNAALDH1A1HSD17B10 | |
| SCHEMBL3524781 | 0.72 | CLK4 (0.45) | KMT2ALMNAALDH1A1SMN1; SMN2GABRA2 | |
| SCHEMBL3523302 | 0.72 | CCNE1 (0.36) | SYKMAPK1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5359257 | 0.69 | ADORA1 (0.41) | ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL3526263 | 0.69 | PDE3B (0.44) | GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709473-B2 | Substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors | PFIZER INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-10-25 | — | — | US | disclosed |
| EP-1678180-B1 | SUBSTITUTED 2H-[1,2,4]TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | SYK 681/4885MAPK1 347/4885KMT2A 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.